CGRP Inhibitors: A Promising New Class of Drugs for Migraine

Article

This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.

In May, the FDA approved erenumab, the first calcitonin gene-related peptide (CGRP) inhibitor for the prevention of migraine in adults. Since then, 2 other CGRP inhibitors have gained approval, providing a new class of drugs for those who suffer from migraine.

This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss the emerging therapy for the condition, which affects 39 million people in the United States.

Log in to listen to the podcast.

Listen above or through one of these podcast services:

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Read more:

FDA Approves Erenumab, First CGRP Inhibitor for Prevention of Migraine

Erenumab for Migraine Is Cost-Effective, but Long-Term Harms Remain Unclear

ICER Releases Final Evidence Report on Efficacy, Cost Effectiveness of CGRP Inhibitors for Migraine

Migraine Survey Highlights Significant Lack of Awareness of CGRP Inhibitors

CGRP Inhibitor Erenumab Shows Efficacy in Migraine Within 1 Week

Related Videos
Vivien Sheehan, MD, PhD, an associate professor of pediatrics at Emory University
Deepak L. Bhatt, MD, MPH, MBA
John A. Charlson, MD
Jeffrey Chamberlain, PhD
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Jonathan W. Weinsaft, MD
Omid Hamid, MD
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital
Robert J. Hopkin, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.